A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis

SUMMARY: The efficacy and safety of RGB-10 and reference teriparatide were evaluated in a randomized 52-week study in 250 patients with osteoporosis at high risk of fracture. RGB-10 was equivalent to reference teriparatide in efficacy and had a comparable safety profile. INTRODUCTION: RGB-10 is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagino, H., Narita, R., Yokoyama, Y., Watanabe, M., Tomomitsu, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795613/
https://www.ncbi.nlm.nih.gov/pubmed/31243480
http://dx.doi.org/10.1007/s00198-019-05038-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795613/
https://www.ncbi.nlm.nih.gov/pubmed/31243480
http://dx.doi.org/10.1007/s00198-019-05038-y

Ejemplares similares